(BCPC) Balchem - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NASDAQ (USA) | Market Cap: 5.179m USD | Total Return: -2.9% in 12m
Avg Turnover: 27.3M
EPS Trend: 97.8%
Qual. Beats: 4
Rev. Trend: 90.9%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Shakeout
Balchem Corporation (BCPC) is a specialty chemicals company headquartered in Montvale, New Jersey, focused on the development and distribution of performance ingredients. The company operates through three primary segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Its portfolio includes microencapsulation solutions, chelated minerals, choline nutrients, and sterilization gases such as ethylene oxide.
The business model relies on proprietary delivery technologies, such as microencapsulation, which protect sensitive ingredients and control their release in both human and animal biological systems. This technical differentiation allows the company to serve diverse end-markets ranging from food and beverage production to medical device sterilization. The specialty chemicals sector typically benefits from high barriers to entry due to stringent regulatory requirements for food-grade and medical-grade chemical manufacturing.
Investors looking for deeper fundamental analysis may find further value in exploring the data on ValueRay. Balchem utilizes a multi-channel distribution strategy, employing a direct sales force alongside independent distributors and agents to reach global industrial and pharmaceutical markets.
- Expansion of Human Nutrition margins through value-added specialty mineral and vitamin sales
- Feed cost volatility and livestock production cycles impact Animal Nutrition segment revenue
- Ethylene oxide regulatory oversight poses operational risks to medical device sterilization business
- Strategic acquisitions and R&D investment drive long-term organic growth in specialty ingredients
- Global food and beverage demand fluctuations influence spray-dried and emulsified powder volumes
| Net Income: 158.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.07 > 1.0 |
| NWC/Revenue: 22.36% < 20% (prev 20.81%; Δ 1.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 220.2m > Net Income 158.1m |
| Net Debt (127.6m) to EBITDA (271.5m): 0.47 < 3 |
| Current Ratio: 2.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.3m) vs 12m ago -1.59% < -2% |
| Gross Margin: 36.27% > 18% (prev 0.36%; Δ 3.59k% > 0.5%) |
| Asset Turnover: 63.86% > 50% (prev 59.63%; Δ 4.23% > 0%) |
| Interest Coverage Ratio: 20.58 > 6 (EBITDA TTM 271.5m / Interest Expense TTM 10.4m) |
| A: 0.14 (Total Current Assets 388.9m - Total Current Liabilities 152.5m) / Total Assets 1.69b |
| B: 0.69 (Retained Earnings 1.16b / Total Assets 1.69b) |
| C: 0.13 (EBIT TTM 214.0m / Avg Total Assets 1.66b) |
| D: 2.93 (Book Value of Equity 1.20b / Total Liabilities 408.6m) |
| Altman-Z'' = 7.09 = AAA |
| DSRI: 1.08 (Receivables 154.2m/130.4m, Revenue 1.06b/964.5m) |
| GMI: 0.98 (GM 36.27% / 35.55%) |
| AQI: 0.97 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.10 (Revenue 1.06b / 964.5m) |
| TATA: -0.04 (NI 158.1m - CFO 220.2m) / TA 1.69b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 161.75 with a total of 121,733 shares traded.
Over the past week, the price has changed by +1.72%,
over one month by -7.66%,
over three months by -7.93% and
over the past year by -2.87%.
Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 200.8 | 24.1% |
P/E Forward = 29.4985
P/S = 4.8984
P/B = 3.9782
P/EG = 3.6902
Revenue TTM = 1.06b USD
EBIT TTM = 214.0m USD
EBITDA TTM = 271.5m USD
Long Term Debt = 169.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.65m USD (from shortTermDebt, last quarter)
Debt = 200.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.7m
Net Debt = 127.6m USD (calculated: Debt 200.4m - CCE 72.9m)
Enterprise Value = 5.31b USD (5.18b + Debt 200.4m - CCE 72.9m)
Interest Coverage Ratio = 20.58 (Ebit TTM 214.0m / Interest Expense TTM 10.4m)
EV/FCF = 30.16x (Enterprise Value 5.31b / FCF TTM 176.0m)
FCF Yield = 3.32% (FCF TTM 176.0m / Enterprise Value 5.31b)
FCF Margin = 16.64% (FCF TTM 176.0m / Revenue TTM 1.06b)
Net Margin = 14.95% (Net Income TTM 158.1m / Revenue TTM 1.06b)
Gross Margin = 36.27% ((Revenue TTM 1.06b - Cost of Revenue TTM 673.8m) / Revenue TTM)
Gross Margin QoQ = 37.34% (prev 35.62%)
Tobins Q-Ratio = 3.13 (Enterprise Value 5.31b / Total Assets 1.69b)
Interest Expense / Debt = 5.19% (Interest Expense 10.4m / Debt 200.4m)
Taxrate = 23.30% (12.2m / 52.5m)
NOPAT = 164.1m (EBIT 214.0m * (1 - 23.30%))
Current Ratio = 2.55 (Total Current Assets 388.9m / Total Current Liabilities 152.5m)
Debt / Equity = 0.16 (Debt 200.4m / totalStockholderEquity, last quarter 1.29b)
Debt / EBITDA = 0.47 (Net Debt 127.6m / EBITDA 271.5m)
Debt / FCF = 0.72 (Net Debt 127.6m / FCF TTM 176.0m)
Total Stockholder Equity = 1.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.55% (Net Income 158.1m / Total Assets 1.69b)
RoE = 12.38% (Net Income TTM 158.1m / Total Stockholder Equity 1.28b)
RoCE = 14.80% (EBIT 214.0m / Capital Employed (Equity 1.28b + L.T.Debt 169.0m))
RoIC = 11.15% (NOPAT 164.1m / Invested Capital 1.47b)
WACC = 6.95% (E(5.18b)/V(5.38b) * Re(7.07%) + D(200.4m)/V(5.38b) * Rd(5.19%) * (1-Tc(0.23)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.11 | Cagr: -0.26%
[DCF] Terminal Value 77.97% ; FCFF base≈165.9m ; Y1≈190.2m ; Y5≈279.9m
[DCF] Fair Price = 127.1 (EV 4.21b - Net Debt 127.6m = Equity 4.08b / Shares 32.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.82 | EPS CAGR: 11.17% | SUE: 1.63 | # QB: 4
Revenue Correlation: 90.90 | Revenue CAGR: 4.83% | SUE: 0.84 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.43 | Chg30d=+1.42% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.50 | Chg30d=+1.01% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=5.68 | Chg30d=-0.02% | Revisions=+0% | GrowthEPS=+10.4% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=6.11 | Chg30d=+0.59% | Revisions=+20% | GrowthEPS=+7.5% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +20%